Sanxin Medtec(300453) 国元证券·2024-10-17 04:00Investment Rating - The report maintains a "Buy" rating for the company, supported by its strong performance and growth prospects [5][7] Core Views - The company's Q1-3 2024 revenue reached 1,082 million yuan, a year-on-year increase of 16.38%, with net profit attributable to shareholders of 168 million yuan, up 18.74% [2] - In Q3 2024, the company achieved revenue of 396 million yuan, a year-on-year increase of 13.69%, and net profit attributable to shareholders of 62 million yuan, up 18.75% [3] - The company's gross margin improved to 35.03% (+0.63pct), and net margin increased to 16.94% (+0.59pct) [3] - The company is expanding its production capacity with a 500 million yuan investment in a high-performance blood purification equipment and consumables project, which is expected to enhance its competitive position in the industry [4] Financial Performance and Projections - The company's revenue is projected to grow from 1,555 million yuan in 2024 to 1,920 million yuan in 2026, with net profit attributable to shareholders increasing from 245 million yuan to 295 million yuan over the same period [5] - EPS is expected to rise from 0.47 yuan/share in 2024 to 0.57 yuan/share in 2026, with P/E ratios declining from 16x to 13x [5] - The company's ROE is forecasted to remain strong, ranging from 16.36% to 18.00% between 2024 and 2026 [6] Operational Efficiency - The company's operating efficiency improved, with a slight decrease in period expense ratios, including a reduction in management expense ratio to 6.76% (-0.43pct) [3] - R&D expenses increased to 4.13% of revenue (+0.45pct), reflecting the company's focus on innovation [3] Industry Position - The company is consolidating its position as a leader in the blood purification consumables market, with its expansion projects expected to further strengthen its market share [4]